Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus rating of “Moderate Buy” by the twenty-one research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, sixteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $1,104.65.

REGN has been the subject of a number of analyst reports. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $1,187.66 on Friday. The company has a 50-day moving average price of $1,084.81 and a 200-day moving average price of $1,001.76. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,203.49. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $130.93 billion, a P/E ratio of 35.09, a PEG ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the firm earned $8.79 earnings per share. The company’s quarterly revenue was up 12.3% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 787 shares of the firm’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the completion of the sale, the chief executive officer now owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The disclosure for this sale can be found here. Insiders sold 17,731 shares of company stock valued at $18,230,142 in the last three months. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Sachetta LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. West Paces Advisors Inc. grew its position in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the last quarter. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $33,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.